Palma-Barqueros V, Revilla N, Zaninetti C, Galera A, Sanchez-Fuentes A, Zamora-Canovas A
Blood Adv. 2022; 6(17):5244-5255.
PMID: 35349645
PMC: 9631645.
DOI: 10.1182/bloodadvances.2021005446.
von Suskil M, Sultana K, Elbezanti W, Al-Odat O, Chitren R, Tiwari A
Int J Mol Sci. 2021; 22(11).
PMID: 34071917
PMC: 8198777.
DOI: 10.3390/ijms22115707.
Wang Q, Pechersky Y, Sagawa S, Pan A, Shaw D
Proc Natl Acad Sci U S A. 2019; 116(19):9390-9399.
PMID: 31019091
PMC: 6511029.
DOI: 10.1073/pnas.1819301116.
Bai X, Zhang Y, Huang L, Wang J, Li W, Niu L
Blood. 2016; 128(13):1723-34.
PMID: 27330000
PMC: 5043127.
DOI: 10.1182/blood-2016-03-703579.
Hamasy A, Wang Q, Blomberg K, Mohammad D, Yu L, Vihinen M
Leukemia. 2016; 31(1):177-185.
PMID: 27282255
PMC: 5220130.
DOI: 10.1038/leu.2016.153.
The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation.
Volmering S, Block H, Boras M, Lowell C, Zarbock A
Immunity. 2016; 44(1):73-87.
PMID: 26777396
PMC: 5030078.
DOI: 10.1016/j.immuni.2015.11.011.
Lipid and Protein Co-Regulation of PI3K Effectors Akt and Itk in Lymphocytes.
Wang X, Hills L, Huang Y
Front Immunol. 2015; 6:117.
PMID: 25821452
PMC: 4358224.
DOI: 10.3389/fimmu.2015.00117.
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.
Zheng X, Ding N, Song Y, Feng L, Zhu J
Cancer Cell Int. 2014; 14(1):32.
PMID: 24693884
PMC: 3984027.
DOI: 10.1186/1475-2867-14-32.
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.
Chavez J, Sahakian E, Pinilla-Ibarz J
Core Evid. 2013; 8:37-45.
PMID: 23717217
PMC: 3662532.
DOI: 10.2147/CE.S34068.
Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.
Chen S, Jiang X, Gewinner C, Asara J, Simon N, Cai C
Sci Signal. 2013; 6(277):ra40.
PMID: 23716717
PMC: 3735445.
DOI: 10.1126/scisignal.2003936.
Targeting pathological B cell receptor signalling in lymphoid malignancies.
Young R, Staudt L
Nat Rev Drug Discov. 2013; 12(3):229-43.
PMID: 23449308
PMC: 7595252.
DOI: 10.1038/nrd3937.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani R, Buggy J, Sharman J, Smith S, Boyd T, Grant B
J Clin Oncol. 2012; 31(1):88-94.
PMID: 23045577
PMC: 5505166.
DOI: 10.1200/JCO.2012.42.7906.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
Gustafsson M, Hussain A, Mohammad D, Mohamed A, Nguyen V, Metalnikov P
Mol Cell Biol. 2012; 32(13):2440-53.
PMID: 22527282
PMC: 3434478.
DOI: 10.1128/MCB.06620-11.
A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells.
Singhal E, Kumar P, Sen P
J Biol Chem. 2011; 286(37):32054-63.
PMID: 21784852
PMC: 3173196.
DOI: 10.1074/jbc.M111.271247.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B
Proc Natl Acad Sci U S A. 2010; 107(29):13075-80.
PMID: 20615965
PMC: 2919935.
DOI: 10.1073/pnas.1004594107.
Conformational snapshots of Tec kinases during signaling.
Joseph R, Andreotti A
Immunol Rev. 2009; 228(1):74-92.
PMID: 19290922
PMC: 2669291.
DOI: 10.1111/j.1600-065X.2008.00740.x.
Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.
Rajaiya J, Hatfield M, Nixon J, Rawlings D, Webb C
Mol Cell Biol. 2005; 25(6):2073-84.
PMID: 15743806
PMC: 1061591.
DOI: 10.1128/MCB.25.6.2073-2084.2005.
A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.
Guo S, Ferl G, Deora R, Riedinger M, Yin S, Kerwin J
Proc Natl Acad Sci U S A. 2004; 101(39):14180-5.
PMID: 15375214
PMC: 521099.
DOI: 10.1073/pnas.0405878101.
Differential regulation of NFAT and SRF by the B cell receptor via a PLCgamma-Ca(2+)-dependent pathway.
Hao S, Kurosaki T, August A
EMBO J. 2003; 22(16):4166-77.
PMID: 12912915
PMC: 175791.
DOI: 10.1093/emboj/cdg401.
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Lee L, Guan J, Qiu Y, Kung H
Mol Cell Biol. 2001; 21(24):8385-97.
PMID: 11713275
PMC: 100003.
DOI: 10.1128/MCB.21.24.8385-8397.2001.